Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Apr 21:5:2050313X17705050.
doi: 10.1177/2050313X17705050. eCollection 2017.

Recovery of methotrexate-induced anuric acute kidney injury after glucarpidase therapy

James Harms  1 , Ayaz Khawaja  2 , Maria Taylor  1 , Xiaosi Han  2 , Michal Mrug  1   3
Affiliations
Case Reports

Recovery of methotrexate-induced anuric acute kidney injury after glucarpidase therapy

James Harms et al. SAGE Open Med Case Rep. .

Abstract

Objectives: This case report describes two cases of high-dose methotrexate-induced nephrotoxicity: death in the case of conventional supportive care and successful renal function recovery in a patient treated with glucarpidase and continuous dialysis.

Methods: High dose methotrexate is widely used for management of adult and pediatric malignancies. However, high-dose methotrexate-induced renal nephrotoxicity may cause severe, even lethal complications. Here we present examples of such outcomes.

Results: We present one case of lethal high-dose methotrexate nephrotoxicity in a patient treated with conventional rescue therapy. We contrast this outcome with another patient with high-dose methotrexate-induced anuric acute kidney injury, who has recovered renal function following therapy with glucarpidase and continuous dialysis.

Conclusions: This is only the second reported case of high-dose methotrexate-induced anuric acute kidney injury, and the only one with a reported clinical outcome. This first report of recovery from high-dose methotrexate-induced anuric acute kidney injury after glucarpidase administration supports available evidence pointing to the effectiveness of this therapy.

Keywords: High-dose methotrexate; acute kidney injury; continuous renal replacement therapy; methotrexate.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
High-dose methotrexate (HDMTX) therapy outcomes. Patient A (left panel) has developed anuric acute kidney injury after HDMTX. However, he has recovered renal function with supportive care that included glucarpidase administration and continuous renal replacement therapy (CRRT). Patient B (right panel) has developed HDMTX-induced AKI that was milder and non-oliguric; however, later died due to complications of severe sepsis.
See this image and copyright information in PMC

References

    1. Widemann BC. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006; 11(6): 694–703. - PubMed
    1. Widemann BC, Balis FM, Kim A, et al. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome. J Clin Oncol 2010; 28(25): 3979–3986. - PMC - PubMed
    1. Albushra Y. Prevention and management of high-dose methotrexate toxicity. J Cancer Sci Therapy 2013; 5(3), https://www.omicsonline.org/1948-5956/JCST-05-106.digital/fscommand/JCST...
    1. Saland J, Leavey P, Bash R, et al. Effective removal of methotrexate by high-flux hemodialysis. Pediatr Nephrol 2002; 17(10): 825–829. - PubMed
    1. Schwartz S, Borner K, Muller K, et al. Glucarpidase (carboxypeptidase G2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy. Oncologist 2007; 12(11): 1299–1308. - PubMed

Publication types

LinkOut - more resources